KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EPS (Basic) (2016 - 2025)

Pacific Biosciences Of California has reported EPS (Basic) over the past 16 years, most recently at -$0.13 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.13 for Q4 2025, down 750.0% from a year ago — trailing twelve months through Dec 2025 was -$1.84 (down 62.83% YoY), and the annual figure for FY2025 was -$1.82, down 61.06%.
  • EPS (Basic) for Q4 2025 was -$0.13 at Pacific Biosciences Of California, roughly flat from -$0.13 in the prior quarter.
  • Over the last five years, EPS (Basic) for PACB hit a ceiling of $0.02 in Q4 2024 and a floor of -$1.44 in Q1 2025.
  • Median EPS (Basic) over the past 5 years was -$0.31 (2023), compared with a mean of -$0.35.
  • Biggest five-year swings in EPS (Basic): plummeted 4600.0% in 2021 and later surged 106.45% in 2024.
  • Pacific Biosciences Of California's EPS (Basic) stood at -$0.33 in 2021, then decreased by 12.12% to -$0.37 in 2022, then increased by 16.22% to -$0.31 in 2023, then soared by 106.45% to $0.02 in 2024, then crashed by 750.0% to -$0.13 in 2025.
  • The last three reported values for EPS (Basic) were -$0.13 (Q4 2025), -$0.13 (Q3 2025), and -$0.14 (Q2 2025) per Business Quant data.